Phase 2 N=28 Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer (NSCLC) · Stage IV NSCLC · Metastatic NSCLC
Primary: Objective Response Rate — 0; 1 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=166 Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer
Primary: Overall Objective Response Rate (ORR) — 8.1; 10.9 percentage of participants
Phase 2 N=288 Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced NSCLC Metastatic Non-small Cell Lung Cancer
Non-small Cell Lung Cancer · Efficacy
Primary: Progression Free Survival (PFS) — 168; 140 day
Phase 2 N=32 Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer
Lung Neoplasms · Carcinoma, Non-small Cell Lung
Primary: Percentage of Participants With Objective Response (OR) — 9.4 Percentage of participants
Phase 2 N=53 The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Best Disease Response After a Maximum of Six Cycles. — 0; 23; 23; 6 Participants
Phase 2 N=69 Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer
Lung Cancer
Primary: Overall Clinical Response Rate — 17 Percentage of participants
Phase 2 N=37 BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma
Primary: Response Rate — 6 percentage of participants
Phase 2 N=153 A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.
Non-small-cell Lung Cancer
Primary: Response Assessment by Study Stratum - Per Investigator Assessment — 0; 6; 3; 7 Participants
Phase 2 N=39 Lower Dose Chemotherapy Given More Frequent With Avastin to Treat Advanced Non-Squamous Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 8.5 months
Phase 2 N=157 A Phase 2 Study of CRLX101(NLG207) in Patients With Advanced Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: To Compare Overall Survival of Patients Treated With CRLX101 + BSC to Those Patients Treated With BSC Only — 6.3; 11.9 months
Phase 3 N=219 Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer
Non-small Cell Lung Cancer
Primary: Progression Free Survival — 9.7; 4.2 months
Phase 2 N=53 Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib
Non-Small Cell Lung Cancer
Primary: Progression-free Survival (PFS) — 3.1; 1.9 months
Phase 2 N=11 LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer
Lung Cancer
Primary: Number of Participants With a Response — 4 Participants — p=0.161
Phase 2 N=103 ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer
Advanced Non-small Cell Lung Cancer (NSCLC)
Primary: Response Rate (Centrally Assessed) — 13.6; 19.6 percentage of participants
Phase 3 N=583 Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer (NSCLC)
Primary: Overall Survival (OS) Time — 16.1; 15.5 months
Phase 2 N=50 Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer
Cancer
Primary: Evaluation of Overall Survival — 50.4 weeks
Phase 2 N=172 A Study in Non-Small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma
Primary: Progression-free Survival (PFS) — 5.45; 5.22 months — p=0.848
Phase 2 N=133 Chemotherapy With Pemetrexed in Combination With Platinum for Advanced Non-Small Cell Lung Cancer (NSCLC)
Non-Small-Cell Lung Cancer
Primary: Percentage of Participants Surviving Progression-Free at 6 Months (Progression Free Survival [PFS] Rate) — 52.8; 39.3 percentage
Phase 2 N=26 Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer
Recurrent Non-Small Cell Lung Carcinoma · Stage IV Non-Small Cell Lung Cancer
Primary: Overall Response Rate (Complete and Partial Response) Defined by RECIST 1.1 Criteria — 0; 9; 6; 6 Participants
Phase 3 N=1,391 ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer
Non-small Cell Lung Cancer · Lung Cancer
Primary: Progression-Free Survival (PFS) in the Overall Population — 17.3; 14 Weeks
Phase 4 N=296 Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer (NSCLC)
Primary: Progression Free Survival (PFS) — 4.8; 2.6 month
Phase 2 N=110 S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer
Adenocarcinoma of the Lung · Adenosquamous Cell Lung Cancer · Bronchoalveolar Cell Lung Cancer
Primary: The Percentage of Patients With Grade 4 (i.e. Life-threatening) Hemorrhage Toxicities Related to Protocol Treatment. — 2 percentage of participants
Phase 3 N=720 PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer
Lung Cancer
Primary: Overall Survival — 6.83; 6.31 Months — p=0.506
Phase 2 N=33 BELotaxel(Docetaxel) and bellOXa(Oxaliplatin) in Advanced NSCLC
Non-Small Cell Lung Cancer
Primary: Response Rate — 11 participants
Phase 3 N=904 A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC)
Carcinoma, Non-Small-Cell Lung
Primary: Overall Survival (OS) in the ITT (Non-squamous) Population — 376; 379 days — p=0.401
Phase 2 N=201 Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: Progression-free Survival — 2.6; 1.8 months
Phase 3 N=939 Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) — 2.89; 2.76; 2.37; 1.54 months — p=0.756
Phase 3 N=542 Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation
Carcinoma, Non-Small-Cell Lung
Primary: Percentage of Participants With Serious Adverse Events (SAEs) — 30.3 Percentage of participants (%)
Phase 3 N=585 BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)
Carcinoma, Non-Small-Cell Lung
Primary: Overall Survival — 11.96; 10.78; 11.73; 10.87 Months — p=0.7428
Phase 2 N=66 A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer
Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma
Primary: Overall Response Rate (ORR) — 0; 3; 19; 2 Participants